Welcome to the Mass General Brigham Innovation Board Mentor page. Below the gallery of featured mentors is a sortable database with real-time search function to identify suitable mentors for aspiring board candidates.
Browse the board mentors below. You can sort each column and real-time search by specialty, expertise, etc.
Fill out the contact form to request an introduction.
| Last | First | Credential | Institution | Title | Biography |
|---|---|---|---|---|---|
| Cunningham | Joe | MD | Santé Ventures | Managing Director | Joe Cunningham is a Founding Partner and Managing Director of Santé Ventures, an early stage life science and healthcare venture capital company based in Austin and Houston, Texas. Prior to this Joe was a healthcare Venture Partner with Austin Ventures and was previously the Vice Chair of the Ascension Health Ventures investment committee. He is also the former Chief Medical Officer of the Providence Health System and Executive Director of the 300-physician Providence Health Alliance, both of which belong to the Ascension Health system. He has extensive management experience and is recognized nationally for his expertise in healthcare delivery systems, physician associations and compensation models. Joe serves on Advisory Boards for both United Healthcare and for Health Services Corporation (BC/BS). He is board certified in both Internal Medicine and Quality Assurance and Peer Review. Dr. Cunningham received his BS and MD degrees from Texas A&M University and his MBA from Baylor University. |
| Eames | Sarah | Russell Reynolds | Managing Director | Sarah Ladd Eames is a senior member of the firm’s Board and CEO Advisory Group, as well as the Health Services and global Life Sciences Practices. She specializes in succession planning and recruiting CEOs, senior executive leaders and board members for healthcare services, health plans, pharmaceutical and diagnostics companies. Sarah serves a diverse group of clients comprised of Fortune 500, mid-cap and emerging growth companies in the United States and Europe. She has recruited for multisite for-profit and private equity healthcare services companies, managed care organizations and integrated delivery systems. Based in New York, she offers clients a broad industry perspective, strategic insights, a consultative approach and rigorous assessment of candidates. Sarah also co-founded the firm’s CEO Roundtable for Healthcare CEOs. A seasoned healthcare industry executive, Sarah possesses more than 25 years of diverse healthcare services and board of director experience in both the public and private sectors, including time with Trinity Health. Prior to joining Russell Reynolds Associates, Sarah was the Deputy Chairman and CEO of publicly-traded Allied Healthcare International, Inc. She also held roles of increasing responsibility at American Hospital Supply Corporation, Apria Healthcare Group, Baxter International and Johnson & Johnson. Sarah received her BA in economics from Northwestern University, Phi Beta Kappa, and her MBA from the University of California, Irvine. She serves on the Board of Directors of the Visiting Nurse Service of New York and the Advisory Board of the Smithsonian Libraries. Sarah is also a member of the Economic Club of New York. | |
| English | Kieran | Spencer Stuart | Partner | Kieran English is a member of Spencer Stuart’s Healthcare Practice. She focuses on senior executive and board director searches within the biotechnology and medical technology markets, with a particular focus on precision medicine. Her clients have ranged from Fortune 500 companies to venture-backed enterprises. Kieran partners with the boards and investors of these organizations to advise them on leadership and talent acquisition issues. She has spent a significant amount of time in the San Francisco, San Diego and Boston markets. As a former executive in the industry, Kieran brings firsthand understanding of the challenges and opportunities facing healthcare leaders. Prior to joining Spencer Stuart, Kieran was a partner with another leading global executive search firm, where she led the creation of the precision medicine practice. Kieran was also instrumental in building the firm’s presence in the Texas healthcare market. Previously, Kieran was director of business development at Geron Corporation, where she was responsible for licensing deals, corporate partnerships, acquisitions and asset management. Kieran also held numerous roles with Novartis/Chiron, most recently as associate director of business development for vaccines and diagnostics. During her tenure, she focused on mergers and acquisitions activity in the oncology and infectious disease areas, licensing deals in the blood safety space and strategic opportunities in the molecular diagnostic industry.Kieran also lived in Paris and was responsible for Chiron’s geographic expansion of blood testing products into the emerging markets. Earlier in her career, she spent a number of years as an analyst with a biotechnology focused hedge fund. Kieran received her B.A. in English literature from Manhattan College and her M.B.A. in finance from Fordham University. She is an active a member of the Personalized Medicine Coalition and the American Red Cross Tiffany Circle. | |
| Formela | Jean-François | MD | Atlas Venture | Partner | Jean-François Formela focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chair of the board of IFM Therapeutics and KDAC Therapeutics, and serves on the boards of F-star, Intellia Therapeutics (NASDAQ: NTLA), Kyn Therapeutics, Navitor, RaNA Therapeutics which he co-founded, and Spero Therapeutics. Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR. DE), NxStage (NASDAQ: NXTM) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), Annovation Biopharma (acquired by The Medicines Company), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca). Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. |
| Hafler | Jason | PhD | Sanofi Ventures | Managing Director | Jason Hafler, PhD, currently serves as Managing Director of Sanofi Ventures. Prior to Sanofi, Hafler was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Hafler was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Hafler was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space. |
| Knight | Stephen | MD | F-Prime Capital | President and Managing Partner | Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Ensoma, Genomics plc, Leyden Labs, Prime Medicine, Proof Diagnostics, Pulmocide and Skyline Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Proteostasis Therapeutics (NASDAQ: PTI), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA) and Semma Therapeutics (acquired by Vertex). Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa. |
| Koppel | Adam | MD, PhD | Bain Capital Life Sciences Fund | Managing Director | Adam M. Koppel, MD, PhD, rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of Aptinyx (NASD: APTX), Cerevel Therapeutics (NASD: CERE), Dicerna Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics (NASD: FHTX) and Solid Biosciences (NASD: SLDB) and is a Board Observer for AavantiBio and ViaCyte. Prior to initially joining Bain Capital in 2003, Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Boston Museum of Science Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. In addition, he sits on the Gann Academy Board of Trustees and CJP’s Budget and Administration Committee. He previously sat on the Board of Temple Beth Elohim in Wellesley MA, from 2014-2017. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science. |
| LaViolette | Paul | SV Health Investors | Managing Partner & COO and Innovation Growth Board Chairman | Paul LaViolette is Managing Partner and Chief Operating Officer at SV Health Investors (SVHI), a venture and growth equity investor in healthcare. He joined SVHI in 2009 and has 40 years of global medical technology management experience. Prior to joining SVHI, LaViolette was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he served as COO, Group President, Cardiovascular, Group President, EndoSurgery, President-Cardiology and President-International. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations as the company grew 20-fold. LaViolette previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). He LaViolette serves on the boards of Bardy Diagnostics, Inc., Cardiofocus, Inc., CSA Medical Inc., Corvia Medical, Inc., Edwards Lifesciences, Inc., Endotronix, Inc., Misonix, Inc., Stimwave LLC, Transenterix, Inc. and Zerigo Health, Inc., as well as the Medical Device Manufacturers Association. LaViolette received his BA in Psychology from Fairfield University and his MBA from Boston College. | |
| McGuire | Terry | Polaris Partners | Partner | As a founding partner of Polaris Partners, Terry McGuire brings more than 25 years of successful early stage investing experience in medical and information technology companies. Prior to starting Polaris in 1996, he spent seven years at Burr, Egan, Deleage & Co. investing in early stage medical and information technology companies. McGuire began his career in venture capital at Golder, Thoma and Cressey in Chicago. As a venture capitalist, McGuire has invested in more than 50 companies. He also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkermes), and MicroCHIPS (private). McGuire has received numerous honors, including the Massachusetts Society for Medical Research Award and the Albert Einstein Award for Outstanding Achievement in the Life Sciences. In 2015, he was listed as one of Scientific American’s Worldview 100, visionaries who continue to reshape biotechnology and the world. In 2014, he received the Irish America Healthcare & Life Sciences 50 Award. In 2013, he was listed as one of Forbes’ Top Life Sciences Investors and he The Boston Irish Business Award. He was awarded honorary doctorate degrees from Ohio Wesleyan University and Canisius College for his work in translational science. McGuire is emeritus chairman of the National Venture Capital Association (NVCA) and a former chairman of the board of the Thayer School of Engineering, Dartmouth College. He is chairman of the Global Venture Capital Congress. He also sits on the boards of MIT’s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and The Healthcare Initiative Advisory Board (HBS). He also serves on the Board of Directors of Cyclerion Therapeutics. McGuire holds an MBA from Harvard Business School, an MS in engineering from The Thayer School at Dartmouth College, and a BS in physics and economics from Hobart College. | |
| Orraca-Cecil | Dede | Egon Zehnder | Consultant, Consumer Practice | Dede Orraca-Cecil is a consultant in Egon Zehnder’s Board, CEO and Leadership Advisory Practices. She consults on a wide range of talent acquisition and leadership solutions to help meet the challenges that many of her clients face as they seek to build and lead best in class organizations. Her prior expertise in corporate governance and public policy have made her a trusted advisor to boards, CEOs, and senior executives on issues of recruitment, team effectiveness, leadership development, and change management. Dede is also a fellow with the Aspen Institute with a focus on helping companies move beyond the rhetoric of Diversity, Equity and Inclusion into practical strategic planning and implementation. Before joining Egon Zehnder, Dede was a Principal in the healthcare practice of Tapestry Networks, a strategy consulting firm specialized in creating multi-stakeholder public-private partnerships to address issues in health care, finance, and corporate governance. Previously, she was an Associate in the New York and San Francisco law offices of Skadden, Arps, Slate, Meagher & Flom, focusing on mass torts, insurance, consumer, and securities litigation. Dede also spent a number of years working in global health, development, and foreign policy with the World Health Organization, the Clinton Foundation, Massachusetts General Hospital, and other organizations. Dede earned a JD from Columbia University School of Law, a master’s degree in global health policy and development from Yale University, and a BA in art history from Williams College. She is passionate about her husband and four young children, and about promoting inclusive leadership. She is currently building an organization, called “She Rules,” to introduce elementary school girls to politics and civics. | |
| Richmond | Russ | MD | Russ Richmond, MD, is a physician and entrepreneur with experience building subscription data-analytics companies such as Advanced Practice Strategies (APS), Validic, PeraHealth, Explorys, Objective Health, Verisk Health, and D2Hawkeye, as well as counseling CEOs of large providers, payors, and health systems as a McKinsey & Company management consultant. Russ was most recently the CEO of APS, a company that is accelerating the reliability in healthcare delivery by measuring and improving clinical knowledge and judgment. APS is based in Boston, MA and currently has about 70 employees. He is currently Executive Chairman of Validic, which is the de-facto standard for device and sensor data in healthcare, and a board director at PeraHealth, which is a provider of predictive, real-time clinical surveillance solutions to hospitals. Russ has experience starting, raising capital for, leading, scaling, and selling companies, but is most proud of creating good places to work with committed and mission-oriented teams. Russ completed his internship in Internal Medicine and Pediatrics at the University of Michigan, and earned his MD from the University of Cincinnati, and a BS in Biology from the University of Michigan. He resides in Newton, MA with his wife and three children. | ||
| Yap | Greg | Menlo Ventures | Partner | Greg is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining in 2017, Greg has led Menlo’s investments in Clear Labs, Delfi Diagnostics, Encoded Therapeutics, Epiodyne, Genesis Therapeutics, H1 Insights, Particle Health, Pliant Therapeutics (NASDAQ: PLRX), Senti Biosciences, and Riva Health. He has also been involved in investments in Benchling, Recursion Pharmaceuticals, and Cofactor Genomics. Previously, Greg was at Illumina Ventures as entrepreneur-in-residence, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: BlueLight Therapeutics (originally Biodesy), a structure- driven platform & therapeutics company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company. Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. He is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Greg is a Bay Area native and has lived in 11 cities in the area. Greg serves on the board of Outward Bound California and loves all manner of outdoor activities with his family, including backpacking and snowboarding. His favorite sport is basketball. |
|
| Siegel | Sue | Board Member, CEO, VC | Sue Siegel has served as a CEO, VC, and Board Director for big and small, public and private corporations, and non-profit organizations. She is a visionary leader known for identifying and seizing transformative opportunities that help organizations generate stakeholder returns, build new markets, and impact lives. She has served on 20 boards over the past 20+ years. Currently, her portfolio includes Illumina (ILMN), Align (ALGN), Nevro (NVRO), the Kaiser Family Foundation, the UC Berkeley Bakar BioEnginuity Hub, and she is Chairman of MIT’s The Engine. Additionally, Siegel is a Lecturer on Entrepreneurship at MIT Sloan School of Management. Siegel served on the non-profit boards of the National Venture Capital Association and Silicon Valley’s Tech Interactive. In addition, she co-chaired Stanford Medicine’s Board of Fellows, Mass General Brigham’s Innovation Growth Board, RAND Health Care, UC Regents I&E Working Group, and the U.K. National Health Services Digital Academy. She also served on President Obama’s Working Group for the Precision Medicine Initiative, was a founding board member of the NIH’s National Center for Advancing Translational Science, and served as a selection judge for White House Fellows across administrations. Siegel served as GE’s Chief Innovation Officer, CEO of GE Ventures & Licensing, and CEO, Healthymagination. Prior to GE, she was a VC General Partner at Mohr Davidow Ventures, leading investments in Life Sciences & Health. During the early days of the Human Genome Project, she led Affymetrix, driving its growth from start up to a multi-billion publicly-listed company that shaped the emerging genomics industry. Her corporate career began after graduate work in molecular biology and biochemistry and leadership roles at BioRad, DuPont, and Amersham. Siegel was named one of Fortune’s “34 Leaders Who Are Changing Health Care” and “The 100 Most Influential Women in Silicon Valley.” She was awarded the “Lifetime Achievement Award” by Global Corporate Venture in 2020. She is an Aspen Institute Henry Crown Fellow and featured in the bestselling book: “Multipliers: How the Best Leaders Make Everyone Smarter.” |
||
| Lubash | Barbara | Director and Advisor for corporate and non-profit boards | Barbara Lubash is a Director and Advisor for corporate and not-forprofit boards. She is a member of Boards of Directors of Hicuity Health, Clew, CareconnectMD, and SolveME. In addition to the Mass General Brigham Innovation Growth Board, she holds advisory roles at STEMAdvantage and the T.H. Chan Harvard School of Public Health Executive Council. In her prior careers as a health care executive, and later as a venture capitalist, Barbara led and advised innovative healthcare and service organizations, and was an early investor in Cogent Healthcare (hospitalists), CodeRyte (NLP), Vantage Oncology (radiation oncology), RedBrick (wellness), among others. She was co-founder and Managing Director of Versant Ventures, and before that a Venture Partner at Crosspoint Ventures. She was Board Chair of California HealthCare Foundation from 2009-2018. Lubash received a BS from Tufts University, and a Master’s in Health Policy and Management from Harvard University. She completed Board of Directors training at Stanford Directors College. | ||
| Hurd | Andy | Cressey and Company | Operating Partner | Andy Hurd is an Operating Partner at Cressey and Company, previously serving as Chief Executive Officer of Mede Analytics, bringing with him over 25 years of experience in healthcare IT, including product and market innovation as well as strategic partnerships.Andy was CEO of Epocrates (NASDAQ: EPOC), which was purchased by athenahealth (NASDAQ: ATHN). Prior to Epocrates, Andyserved as chairman and CEO of Carefx, which was acquired by Harris Corporation (NYSE: HRS) in 2011. During his six-year tenure at Carefx, the company achievedstrong growth in revenue, income and shareholder value. Before Carefx, Hurdheld senior management positions at WebMD, LLC (NASDAQ: WBMD) and QuadraMed Corporation.Andy holds a bachelor’s degree in business administration from Northern Arizona University, and he is a member of the board of directors of Ability Networks and the Cleveland Clinic Innovations Advisory Board. | |
| Davis | Tamara | Davis Board Services LLC | Managing Director | Tamara P. Davis leads Davis Board Services, LLC, bringing a fresh approach to governance consulting and Board Director recruitment. Emphasis is placed on effective, strategic corporate governance which directly contributes to improved shareholder value and results in a high performing Board. Tamara’s extensive leadership experience with both public and private corporate Boards gives her a clear understanding of the potency of an effective governance team. Responsive to the issues, challenges, and responsibilities facing corporate Boards of both entrepreneurial and mature companies, Tamara is committed to strengthening the performance of Boards, by providing customized governance consulting services and identifying and recruiting distinguished Board Director candidates who bring expert, diverse perspectives and competencies tailored to the client’s needs. Tamara Davis’ vast experience, expertise, and innovative approach to Board Director recruitment, Board development, assessment and performance make her a powerful resource for client companies seeking service excellence and expert advice in building a high performing Board. | |